PepKon
Paris, France· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
PepKon is a French biotechnology company founded in 2018, based in Paris, focused on developing first-in-class therapeutic peptides for oncology. The company's platform designs peptides that mimic the cell-binding domain of thrombospondin-1 (TSP-1) to target the CD47 pathway, aiming to induce immunogenic cell death in cancer cells. Its lead candidate, PKT16, is being developed for hematological malignancies and solid tumors.
RNA & Gene Therapy